IRIS
FUMAROLA, Claudia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.747
AS - Asia 3.854
EU - Europa 3.260
SA - Sud America 534
AF - Africa 217
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 2
Totale 12.624
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.660
SG - Singapore 1.339
CN - Cina 1.075
IT - Italia 897
VN - Vietnam 638
IE - Irlanda 433
BR - Brasile 415
FI - Finlandia 411
SE - Svezia 393
DE - Germania 296
HK - Hong Kong 284
FR - Francia 159
UA - Ucraina 133
ZA - Sudafrica 130
NL - Olanda 115
GB - Regno Unito 106
IN - India 105
TR - Turchia 87
RU - Federazione Russa 79
AT - Austria 54
CA - Canada 50
BE - Belgio 49
AR - Argentina 48
CI - Costa d'Avorio 41
BD - Bangladesh 39
KR - Corea 32
PL - Polonia 32
IQ - Iraq 31
JP - Giappone 28
ID - Indonesia 27
ES - Italia 25
MX - Messico 22
CZ - Repubblica Ceca 21
PK - Pakistan 21
CO - Colombia 20
EC - Ecuador 20
PH - Filippine 19
TH - Thailandia 17
PS - Palestinian Territory 12
VE - Venezuela 11
JO - Giordania 10
LT - Lituania 10
MA - Marocco 10
SA - Arabia Saudita 10
EG - Egitto 9
IR - Iran 9
UZ - Uzbekistan 8
KE - Kenya 7
AU - Australia 6
HU - Ungheria 6
LB - Libano 6
LU - Lussemburgo 6
MY - Malesia 6
AE - Emirati Arabi Uniti 5
AL - Albania 5
KG - Kirghizistan 5
NP - Nepal 5
PY - Paraguay 5
SY - Repubblica araba siriana 5
BO - Bolivia 4
CH - Svizzera 4
CL - Cile 4
MD - Moldavia 4
NZ - Nuova Zelanda 4
OM - Oman 4
PE - Perù 4
PT - Portogallo 4
QA - Qatar 4
RO - Romania 4
TN - Tunisia 4
TW - Taiwan 4
AZ - Azerbaigian 3
DZ - Algeria 3
JM - Giamaica 3
PA - Panama 3
UY - Uruguay 3
AO - Angola 2
CY - Cipro 2
DO - Repubblica Dominicana 2
EE - Estonia 2
ET - Etiopia 2
GA - Gabon 2
GE - Georgia 2
IL - Israele 2
KZ - Kazakistan 2
NO - Norvegia 2
SN - Senegal 2
TG - Togo 2
XK - ???statistics.table.value.countryCode.XK??? 2
AD - Andorra 1
AM - Armenia 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
BW - Botswana 1
BY - Bielorussia 1
CR - Costa Rica 1
DM - Dominica 1
GR - Grecia 1
GT - Guatemala 1
Totale 12.607
Salva come PNG Salva come JPEG
Città #
Singapore 738
Dallas 628
Ashburn 494
Dublin 433
Chandler 392
San Jose 345
Ann Arbor 338
Parma 289
Santa Clara 275
Hong Kong 264
Beijing 225
Ho Chi Minh City 180
Dearborn 155
Jacksonville 144
Hanoi 138
Boardman 131
Johannesburg 123
New York 120
Los Angeles 115
Shanghai 99
Munich 92
Hefei 88
Nanjing 85
Lauterbourg 75
Milan 75
Princeton 67
Izmir 65
Bremen 60
Council Bluffs 53
Helsinki 50
Chicago 49
Vienna 46
Abidjan 41
Nanchang 41
São Paulo 41
San Mateo 40
Shenyang 37
Buffalo 34
Modena 34
Moscow 34
The Dalles 34
Wilmington 34
Bologna 33
Brussels 31
Haiphong 31
Kunming 28
Columbus 27
Hebei 27
Da Nang 26
Jinan 24
Marseille 24
Tianjin 24
Frankfurt am Main 23
Seattle 23
Seoul 23
Warsaw 23
Des Moines 22
Jakarta 21
London 21
Tokyo 21
Toronto 21
Redmond 20
Turku 20
Stockholm 19
Denver 18
Nuremberg 17
Woodbridge 17
Manchester 15
Phoenix 15
Pune 15
Amsterdam 14
Atlanta 14
Chennai 14
Guangzhou 14
Norwalk 14
Orem 14
Reggio Emilia 14
Bari 13
Changsha 13
Poplar 13
Rio de Janeiro 13
Boston 12
Brescia 12
Jiaxing 12
Montreal 12
Neviano degli Arduini 12
Rome 12
Wayne 12
Dhaka 11
Leawood 11
New Delhi 11
Baghdad 10
Biên Hòa 10
Florence 10
Fremont 10
Houston 10
Zhengzhou 10
Brasília 9
Brooklyn 9
Gaza 9
Totale 7.784
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 350
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 258
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 246
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 243
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 239
Novel activity of a synthetic decapeptide against Toxoplasma gondii Tachyzoites 210
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 210
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 210
Cell size reduction induced by inhibition of the mTOR/S6K signaling pathway protects Jurkat cells from apoptosis 202
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 198
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 193
Characterization of gefitinib uptake in NSCLC cell lines 189
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 189
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 188
A Photoactive Supramolecular Complex Targeting PD-L1 Reveals a Weak Correlation between Photoactivation Efficiency and Receptor Expression Levels in Non-Small-Cell Lung Cancer Tumor Models 182
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 182
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 180
Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lung 180
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 180
Anti-proliferative effect of letrozole and sorafenib in MCF-7/AROM-1 breast cancer cells 179
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 177
Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress 177
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 177
Anti-proliferative effect of combining Letrozole with Sorafenib in MCF-7/Arom-1 breast cancer cells 176
Antiproliferative and proapototic effects of a new combi-molecule on non small cell lung cancer cell lines 174
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 173
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 173
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 172
Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line 169
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 169
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 168
Anti-proliferative effects of copper(II) complexes with hydroxyquinoline-thiosemicarbazone ligands 168
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells (Frontiers in Oncology, (2022), 12, (942341), 10.3389/fonc.2022.942341) 168
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 167
Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line 166
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 166
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 163
CDK4/6 INHIBITORS AS A NEW THERAPEUTIC APPROACH IN MESOTHELIOMA MODELS 158
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 157
Anti-proliferative and pro-apoptotic effects of Sorafenib in breast cancer cells in vitro. 157
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 156
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 154
Cancer of Unknown Primary: novel therapeutic opportunities from patient-derived cell cultures and in vivo models 154
Effects of FGFR1 inhibition on survival, proliferation, and energy metabolism in Non Small Cell Lung Cancer (NSCLC) cell lines 152
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors) 145
Physico-chemical characterization and biological evaluation of two fibroin materials 144
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 142
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells 136
Targeting FGFR1 pathway in non small cell lung cancer both in vitro and in vivo 132
Changes in glucose uptake after erlotinib treatment in NSCLC cell lines: a predictive and prognostic value? 132
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells 131
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib 130
Overcoming Palbociclib Resistance by Combined Treatment with PI3K/AKT/mTOR Inhibitors in Mesothelioma Cells 130
Role of sphingolipid metabolism in osimertinib-resistance in EGFR-mutated NSCLC models 128
Synergistic activity of letrozole and sorafenib on MCF7/AROM-1 breast cancer cells 126
Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation 125
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines 124
Effect of constitutive or inducible expression of the FHIT gene in a lung cancer cell line 124
Targeting oncogenic PI3K/Akt/mTOR pathway in squamous cell lung carcinoma 120
Modulazione della riespressione del gene FHIT in cellule di carcinoma polmonare 119
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones 117
Immunotherapeutic approaches in malignant pleural mesothelioma 115
Correction to: Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer (Cancers, (2020), 12, 3, (666), 10.3390/cancers12030666) 114
Impairing energy metabolism in solid tumors through agents targeting oncogenic signaling pathways 111
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines 110
Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer 109
Correction to: The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells (Journal of Experimental & Clinical Cancer Research, (2018), 37, 1, (72), 10.1186/s13046-018-0741-3) 106
Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary 105
Synergistic activity of letrozole and sorafenib on breast cancer cells 105
Espressione Inducibile del gene FHIT in cellule di carcinoma polmonare 104
Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines 103
Effect of inducible FHIT and p53 expression on CALU-1 cell proliferation. 100
Synergic anti-proliferative effect of gefitinib and RAD001 in non small cell lung cancer cell lines 100
Effect of letrozole and sorafenib on cell proliferation and apoptosis of MCF-7/AROM-1 breast cancer cell line 99
Targeting FGFR1 pathway in squamous cell lung cancer 96
Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer 95
Increased level of inducible HSP70 in cells exposed to electromagnetic fields. 94
Erlotinib potentiates Cetuximab-dependent call citotoxicity in EGFR wild type NSCLC cell lines 93
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators 89
Studio dell’espressione del gene FHIT in cellule di carcinoma polmonare 89
Pure anti-tumor effect of zoledronic acid in naive bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy" 89
Evaluation of gefitinib maintenance in an EGFR-mutant NSCL cell line with acquired resistance 81
New therapeutic strategies for malignant pleural mesothelioma 81
Effect of inducible Fhit and p53 expression in Calu-1 lung cancer cell line 76
Effect of constitutive expression of the fragile histidine triad gene on non small cell lung cancer 67
Effects of sorafenib on energy metabolism in breast cancer cells: Role of AMPK-mTORC1 signaling 33
null 31
Totale 12.799
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.087
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.087
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021176 0 0 0 0 0 0 0 0 0 23 113 40
2021/2022418 36 15 21 38 15 10 70 30 21 19 30 113
2022/20231.685 147 178 118 107 158 192 14 141 527 9 73 21
2023/2024800 38 49 28 43 54 156 67 68 33 45 89 130
2024/20252.438 87 110 167 178 249 259 177 124 283 199 205 400
2025/20265.050 427 480 797 537 721 275 590 172 710 341 0 0
Totale 12.799